Amphetamines and related drugs in motor recovery after stroke.
Studies in laboratory animals indicate that the rate and extent of functional recovery after focal brain injury can be modulated by drugs affecting specific central neurotransmitters. Preliminary clinical studies suggest that similar drug effects may occur in humans recovering from stroke. Combined with principles derived from the laboratory, these clinical studies provide important insights to guide the rational design of trials aimed at determining the clinical use of this approach to improving poststroke recovery.
Goldstein
Larry B
LB
Center for Cerebrovascular Disease, Department of Medicine (Neurology), Center for Clinical Health Policy Research, Duke University, Durham, North Carolina 27710, USA. golds004@mc.duke.edu
D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003913:Dextroamphetamine / Q000627:therapeutic use*; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use*; D009044:Motor Cortex / Q000503:physiopathology*; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000150:complications* / Q000503:physiopathology*
D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D003913:Dextroamphetamine